According to WHO, 70% of population in developing countries and 30% in developed countries are infected with Helicobacter pylori. This increases the risk of gastritis (B type), gastric and duodenal ulcers and is also linked to the development of the cancer. Currently, diseases caused by H. pylori are treated with drugs that are not acting in a specific manner and therefore they destroy also natural intestinal microflora leading to reinfection and enhanced resistance of H. pylori to standard drugs.
For commercialisation we offer a group of low molecular compounds inhibiting growth of Helicobacter pylori through blocking the interaction of proteins initiating the chromosome replication, that is necessary for survival of H. pylori cells.
In addition, we offer a method for identification of compounds blocking the interaction of selected Helicobacter pylori proteins, that might be applied in the treatment or prevention of infections caused by H. pylori. This method consists of an immunoenzymatic test, two-hybrid test and disc-diffusion test.
Offered compounds selectively block interactions between HobA and DnaA proteins of H. pylori, but they are not affecting the interactions of homologous proteins of other microorganisms. The compounds enable efficient and targeted therapy of infections caused by Helicobacter pylori.
- Treatment and prevention of infections caused by Helicobacter pylori
- Identification of compounds inhibiting growth of Helicobacter pylori cells
Posted by Agata Kołacz, Posted on 20.05.2016